Background:
- TMB-H was reported to be predictive of response to immune checkpoint inhibitors[1-2].
- However, genomic signatures contributing to TMB-H independent from dMMR/MSI-H status are not well-studied.
- We aimed to characterize specific molecular features of a large cohort of MSS GI tumors with TMB-H.
Conclusion:
- This is the largest study to investigate the distinct molecular landscape of dMMR/MSI-H GI cancers with different degrees of TMB. These data may inform our understanding of the efficacy of ICB in dMMR/MSI-H GI tumors.